Granger, C. B., Lopes, R. D., Hanna, M., Ansell, J., Hylek, E. M., Alexander, J. H., … Wallentin, L. (2015). Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the ARISTOTLE trial (vol 169, pg 25, 2014). AMERICAN HEART JOURNAL, 169(4), 594–594.

Granger, C. B., R. D. Lopes, M. Hanna, J. Ansell, E. M. Hylek, J. H. Alexander, L. Thomas, et al. “Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the ARISTOTLE trial (vol 169, pg 25, 2014).” AMERICAN HEART JOURNAL 169, no. 4 (2015): 594–594.

Granger CB, Lopes RD, Hanna M, Ansell J, Hylek EM, Alexander JH, et al. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the ARISTOTLE trial (vol 169, pg 25, 2014). AMERICAN HEART JOURNAL. 2015;169(4):594–594.

Granger, C. B., et al. “Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the ARISTOTLE trial (vol 169, pg 25, 2014).” AMERICAN HEART JOURNAL, vol. 169, no. 4, 2015, pp. 594–594.

Granger CB, Lopes RD, Hanna M, Ansell J, Hylek EM, Alexander JH, Thomas L, Wang J, Bahit MC, Verheugt F, Lawrence J, Xavier D, Wallentin L. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the ARISTOTLE trial (vol 169, pg 25, 2014). AMERICAN HEART JOURNAL. 2015;169(4):594–594.